Celcuity to Participate in Cowen’s 44th Annual Health Care Conference
February 28 2024 - 7:05AM
Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology
company pursuing development of targeted therapies for oncology,
today announced its participation in Cowen’s 44th Annual Health
Care Conference to be held in Boston on March 4-6, 2024.
Brian Sullivan, Chief Executive Officer, and Co-founder of
Celcuity, is scheduled for a fireside chat at 2:10 p.m. ET on
Wednesday, March 6, 2024. A live webcast of the event will be
available using this weblink
https://wsw.com/webcast/cowen154/celc/1980218. Alternatively, the
live webcast will be accessible from the Investors section of the
company's website at https://ir.celcuity.com/events-presentations/
with a replay available shortly after.
About Celcuity
Celcuity is a clinical-stage biotechnology company focused on
development of targeted therapies for treatment of multiple solid
tumor indications. The company's lead therapeutic candidate is
gedatolisib, a potent, pan-PI3K and mTOR inhibitor. Its mechanism
of action and pharmacokinetic properties are highly differentiated
from other currently approved and investigational therapies that
target PI3K or mTOR alone or together. A Phase 3 clinical trial,
VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant
with or without palbociclib in patients with HR+/HER2- advanced
breast cancer is currently enrolling patients. More detailed
information about the VIKTORIA-1 study can be found at
ClinicalTrials.gov. A Phase 1b/2 clinical trial, CELC-G-201,
evaluating gedatolisib in combination with darolutamide in patients
with metastatic castration resistant prostate cancer, is currently
enrolling patients. The company's CELsignia companion diagnostic
platform is uniquely able to analyze live patient tumor cells to
identify new groups of cancer patients likely to benefit from
already approved targeted therapies. Further information about
Celcuity can be found at Celcuity.com. Follow us on LinkedIn and
Twitter.
Contacts:
Celcuity Inc.Brian Sullivan, bsullivan@celcuity.comVicky Hahne,
vhahne@celcuity.com(763) 392-0123
ICR WestwickeMaria Yonkoski, maria.yonkoski@westwicke.com(203)
682-7167
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Celcuity (NASDAQ:CELC)
Historical Stock Chart
From Aug 2023 to Aug 2024